Pharmafile Logo
Pharmafocus logo
Advanced Search

Takeda

Showing 15 posts of 242 posts found.

takeda_usa_pharmaceuticals_u

NICE recommend Takeda’s lymphoma treatment Adcetris

March 25, 2019
Sales and Marketing Cancer, NICE, Takeda, UK, lymphoma, oncology, recommendation

Britain’s cost effectiveness body has recommended Takeda’s Adcetris (brentuximab vedotin) for adult patients with CD-30 positive advanced cutaneous T-cell lymphoma …

News
takeda_usa_pharmaceuticals_u

Takeda’s Adcetris secures expanded approval in Europe for untreated CD30+ Stage IV Hodgkin lymphoma

February 14, 2019
Sales and Marketing Adcetris, Cancer, Europe, Hodgkin lymphoma, Takeda, pharma

Takeda’s Adcetris (brentuximab vedotin) has seen its marketing authorisation expanded by the European Commission to include the treatment of previously …

News
shirelabsus

Takeda ordered to pay Bayer $155.19 million over patent infringement

February 6, 2019
Research and Development Baxalta, Bayer, Nektar Therapeutics, Takeda, adynovate

A US court has ordered Takeda Pharmaceutical’s Baxalta unit to pay German firm Bayer AG $155.19 million for infringement of …

News
takeda_usa_pharmaceuticals_u

Takeda’s dengue vaccine proves efficacious in massive Phase 3 trial

January 30, 2019
Research and Development Dengue fever, TAK-003, Takeda, Vaccine, dengue, health, infectious diseases

Takeda’s dengue vaccine candidate TAK-003, has proved efficacious in preventing dengue fever in healthy children and adolescents in an ongoing …

News
top_10_image

Top Ten most popular articles on Pharmafile.com this week!

January 11, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Bristol-Myers Squibb, Shire, Takeda, bristol myers squibb, death row, pharma, top 10

With the completion of Takeda’s £46 billion acquisition of Shire finally done, another even bigger merger was announced as US …

News
takeda_global_hq

Takeda completes Shire acquisition

January 8, 2019
Manufacturing and Production M&A, MA, Shire, Takeda, acquisition, deal, pharma

Japanese firm Takeda Pharmaceuticals has successfully completed its acquisition of Shire Plc. The long anticipated deal has propelled the firm …

News
takeda_usa_pharmaceuticals_u

Takeda unveils three new discovery and development collaborations in immuno-oncology

January 4, 2019
Medical Communications, Research and Development CAR-T, Crescendo Biologics, Memorial Sloan Kettering Cancer Center, Noile-Immune, Takeda, pharma

Takeda has revealed that it is set to bolster its novel immuno-oncology portfolio with three new research collaborations. The Japanese …

News
top_10_image

Top Ten most popular articles on Pharmafile.com this week!

December 7, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bayer, Cancer, Diagnostics, Sanofi, Takeda, brexit

Takeda’s acquisition of Shire finally got the go-ahead this week as 88% of shareholders voted in favour of French CEO …

News

Takeda shareholders approve $62bn Shire acquisition

December 6, 2018
Business Services Ireland, Japan, M&A, MA, Shire, Takeda, acquisition

Japanese firm Takeda have gained shareholders’ approval for the $62 billion acquisition of the Irish headquartered company Shire Plc. The …

News
takeda_usa_pharmaceuticals_u

European approval for Takeda’s Alunbrig in ALK+ advanced non-small cell lung cancer

November 27, 2018
Research and Development, Sales and Marketing Alunbrig, Cancer, Takeda, lung cancer, pharma

Takeda’s Alunbrig (brigatinib) has been granted marketing approval by the European Commission as a monotherapy to treat anaplastic lymphoma kinase-positive …

News

Takeda’s subcutaneous vedolizumab proves efficacious in Phase III trial for Ulcerative Colitis

October 22, 2018
Sales and Marketing Takeda, UC, biologic, phase III, results, ulcerative colitis, vedolizumab

Japanese pharma firm Takeda has announced that the gut-selective biologic vedolizumab when taken as a subcutaneous (SC) injection, proved efficacious …

News
takeda_usa_pharmaceuticals_u

Takeda’s lung cancer treatment Alunbrig proves successful in Phase III trial

September 26, 2018
Research and Development Alunbrig, R&D, Takeda, phase III, research

Japanese pharma firm Takeda have announced that lung cancer treatment Alunbrig has proven successful in reducing the risk of disease …

News

Shares in Molecular Templates surge after the announcement of Takeda collaboration

September 20, 2018
Business Services, Research and Development Molecular Templates, Shares, Takeda, markets, stocks

Shares in the Texas based biotech Molecular Templates have soared after the company announced that they would be collaborating with …

News

Takeda set to move from Deerfield Illinois, 1000 jobs affected

September 12, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Jobs, Shire, Takeda, deerfield, illinois

Japanese multinational Takeda is set to shut down its US headquarters in Deerfield, Illinois following the final stages of its …

News
omeros_logo_home_resized

Sanofi’s Dr Eckhard Leifke joins Seattle-based biotech Omeros

August 6, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Dr Eckhard Leifke, Omeros, Sanofi, Seattle, Takeda

The Seattle-based biotech Omeros have announced that Sanofi’s Dr Eckhard Leifke will join the commercial-stage biopharmaceutical company as Chief Medical …

Appointment

Latest content

GSK shares data from global shingles survey

December 1, 2023

AbbVie to acquire ImmunoGen for approximately $10.1bn

December 1, 2023

FDA accepts NDA for Karuna’s schizophrenia treatment

November 30, 2023

Vivos Therapeutics gains FDA 510(k) clearance for sleep apnea treatment device

November 30, 2023

Tolremo doses first patient in phase 1 trial for drug to combat transcriptional cancer drug resistance

November 29, 2023